TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation

NCT01300611 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Double Cord Blood Transplant
Acute Myelogenous Leukemia
Myelodysplastic Syndrome
Myelofibrosis
Acute Lymphoblastic Leukemia
Chronic Myelocytic Leukemia
Non Hodgkins Lymphoma
Hodgkins Lymphoma
Chronic Lymphocytic Leukemia

Interventions

DRUG: TXA127 300 mcg/kg/day
DRUG: TXA127 1000 mcg/kg/day

Sponsor

Tarix Pharmaceuticals

Collaborators

[object Object]